

Selected References for Further Reading

1. Brunton LL, Chabner BA, Knollman BC (Eds): Goodman and Gilman's *The Pharmacological Basis of Therapeutics*: 12th edn: McGraw-Hill, New York, **2011**.
2. McPhee SJ, Papadakis MA, Rabow MW (Eds): *Current Medical Diagnosis and Treatment 2012*: Lange Medical Books/McGraw-Hill, New York, **2012**.
3. Sweetman SC (Ed): *Martindale, The Complete Drug Reference*: 37th edn: The Pharmaceutical Press, The Royal Pharmaceutical Society of Great Britain, London, **2011**.
4. *British National Formulary*, No 62; BMJ Publishing Group and RPS Publishing, London, **2011**.
5. Katzung BG, Masters SB, Trevor AJ (Eds): *Basic and Clinical Pharmacology*: 12th edn: Lange medical book, Tata McGraw-Hill, New Delhi, **2012**.
6. Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G: *Pharmacology*: 7th edn: Elsevier, Churchill Livingstone, Edinburgh, **2012**.
7. Bennett PN, Brown MJ: *Clinical Pharmacology*: 10th edn: Churchill Livingstone, Edinburgh, **2008**.
8. *Essential Medicines, WHO Model List*: 17th edn, WHO, Geneva (March **2011**).
9. *National List of Essential Medicines* (2011). Govt. of India, Ministry of Health & Family Welfare, Directorate General of Health Services, New Delhi, **2011** [<http://www.cdsc.nic.in>].
10. Agarwal AK, Singhal RK, Jain DG, Upadhyay R, Rewari BB (Eds): *Emergency Medicine*; Association of Physicians of India, Delhi State Chapter, Jaypee Brothers, New Delhi, **2005**.
11. Morgan GE, Mikhail MS, Murray MJ: *Clinical Anaesthesiology*: 4th edn: Lange Book, Tata McGraw Hill, New Delhi, **2006**.
12. Kar HK, Kumar B: *IAL Textbook of Leprosy*: Jaypee Brothers Medical Publishers, New Delhi, **2010**.
13. *DOTS-Plus guidelines*: Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare, Govt. of India, New Delhi, **2010**.
14. *Treatment of Tuberculosis: Guidelines*, 4th edn: WHO, Geneva, **2010**.
15. Girdhar BK, Girdhar A: Short course treatment of leprosy: present status. *ICMR Bulletin* 32(2): 13-19, **2002**.
16. *Antiretroviral therapy guidelines for HIV infected adults and adolescents, including post-exposure*; NACO, Department of AIDS Control, Min. of Health and Family Welfare, Govt. of India, **2007** [<http://www.nacoonline.org>].
17. *Guidelines for the Treatment of Malaria*, 2nd edn: WHO, Geneva. **2010** [<http://www.who.int/malaria/publications/atoz/978924154925/en/index.html>]
18. National Drug Policy on Malaria (2010), Directorate of National Vector Borne Disease Control Programme, DGHS, Govt. of India, **2010**.
19. *Kala azar Treatment Policy* (2011), Directorate of National Vector Borne Disease Control Programme. DGHS, Govt. of India, **2011**.
20. Expert committee on control of Leishmaniasis; *WHO Technical Report Series No. 949*: Geneva, **2010**.
21. List of drugs banned for marketing in India; Drugs Control Organisation, Govt of India; http://www.drugscontrol.org/ban_drugs.htm.
22. Sharma HL, Sharma KK: *Principles of Pharmacology*: 2nd edn; Paras Medical Publisher, Hyderabad, **2011**.
23. Rubin P (Ed): *Prescribing in Pregnancy*: 3rd edn: BMJ Books, London, Jaypee Brothers, New Delhi (Indian edition 2001), **2000**.
24. Project Team of the Resuscitation Council (UK): Emergency medical treatment of anaphylactic reactions: consensus guidelines; *Resuscitation* 41: 93-99, **1999**.
25. Jiménez-Ruiz C, Berlin I, Hering T: Varenicline: a novel pharmacotherapy for smoking cessation. *Drugs* 69 (10), 1319-38, **2009**.
26. Breslier RS, et al: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial, Adenomatous polyp prevention on viox (APPROVe). *N Engl J Med* 352: 1092-1102, **2005**.
27. Kearney PM, et al: Do selective COX-2 inhibitors and traditional NSAIDs increase the risk of atherothrombosis? Meta-analysis of randomized trials. *BMJ* 332: 1302-1308, **2006**.
28. Schnitzer TJ: Update on guidelines for the treatment of chronic musculoskeletal pain. *Clin Rheumatol* 25: (Suppl 7) 22-29, **2006**.
29. Heyneman CA, Lawless-Liday C, Wall GC: Oral versus topical NSAIDs in rheumatic diseases: a comparison; *Drugs* 60: 555-574, **2000**.
30. Roy AD, Richard BH: Topical therapies for osteoarthritis. *Drugs* 71(10), 1259-79, **2011**.
31. Diabetes control and complications trial (DCCT) Group: Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus; *JAMA* 287: 2563-2569, **2002**.

32. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulfonylureas or insulin compared with conventional regimen and risk of complications in patients with type 2 diabetes (UKPDS 33); *Lancet* 352: 837-853, **1998**.
33. Diabetes Prevention Programme (DPP) research group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 346: 393-403, **2002**.
34. Dormandy JA, *et al*: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study: A randomized controlled trial. *Lancet* 366: 1280, **2005**.
35. Ramirez MA, Borja NL: Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy. *Pharmacotherapy* 28(5), 646-55, **2008**.
36. Gupta V, Kalra S: Choosing a gliptin. *Indian J Endocrinol Metab.* 15 (4), 298-308, **2011**.
37. Vandekerckhove P, Lilford R, *et al*: Withdrawn: Androgens versus placebo or no treatment for idiopathic oligo/asthenospermia. *Cochrane Database Syst Rev* 2007 Jul 18; (4): CD000150; <http://www.ncbi.nlm.nih.gov/pubmed/17636603>.
38. McKeage K, Croxtall JD: Ulipristal acetate: a review of its use in emergency contraception. *Drugs* 71 (7), 935-45, **2011**.
39. Anderson GL, *et al*: The Women's Health Initiative (WHI) randomized controlled trial: Effect of conjugated equine estrogens in post-menopausal women with hysterectomy. *JAMA* 291: 1701-1712, **2004**.
40. Espeland MA, *et al*: The WHI-memory study: Conjugated equine estrogens and global cognitive function in postmenopausal women. *JAMA* 291: 2959-2968, **2004**.
41. Rossouw JE, *et al*: The WHI trial, risks and benefits of estrogens + progestin in healthy postmenopausal women; principal results. *JAMA* 288: 321-333, **2002**.
42. Beral V, *et al*: Million Women Study (MWS): Breast cancer and hormone replacement therapy. *Lancet* 362: 419-427, **2003**.
43. Grady D, Herrington D, *et al*: Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and estrogen/progestin replacement study follow-up (HERS II); *JAMA* 288: 49-57, **2002**.
44. Yang LPH, Keam SJ: Sugammadex: a review of its use in anaesthetic practice. *Drugs* 69 (7), 919-42, **2009**.
45. Parkinson Study Group: Pramipexole vs levodopa as initial treatment for Parkinson's disease, A randomized controlled trial. *JAMA* 284: 1931-1938, **2000**.
46. Hadjipavlou G, Mok H, Yatham LN: Pharmacotherapy of bipolar II disorder: a critical review of current evidence. *Bipolar Disord* 6: 14-25, **2004**.
47. Dhillon S: Aripiprazole: a review of its use in the management of mania in adults with bipolar I disorder. *Drugs* 72 (1), 133-62, **2012**.
48. Lee F, Cundiff D: Meperidine vs morphine in pancreatitis and cholecystitis; *Arch Intern Med* 158: 2399, **1998**.
49. Yusuf S, Sleight P, *et al*: Effects of an angiotensin-converting enzyme inhibitor ramipril, on cardiovascular events in high risk patients. The Heart Outcomes Prevention Evaluation (HOPE) study investigators; *N Engl J Med* 342: 145-153, **2000**.
50. Packer M, Poole-Wilson PA, *et al*: Comparative effects of low and high doses of the angiotensin converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS study Group; *Circulation* 100: 2312-2318, **1999**.
51. EUROPA investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease; European trial on the reduction of cardiac events with perindopril in stable coronary artery disease. *Lancet* 362: 782-788, **2003**.
52. Pfeffer MA, *et al*: Valsartan, captopril or both in myocardial infarction complicated by heart failure, left ventricular dysfunction or both; Valsartan in acute myocardial infarction trial (VALIANT). *New Engl J Med* 349: 1893-1896, **2003**.
53. Mc Murray JJ, *et al*: Effect of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking ACE inhibitors. The CHARM-Added Trial. *Lancet* 362: 767-771, **2003**.
54. Chaitman BR: Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. *Circulation* 113: 2462-2472, **2006**.
55. Chobanian AV, *et al*: The 7th report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure: The JNC7 report; *JAMA* 289: 2560-2572, **2003**.
56. Whitworth JA: World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. *J Hypertens* 21: 1983, **2003**.
57. ALLHAT officers, *et al*: Major outcomes in high-risk hypertensive patients randomized to ACE inhibitor or calcium channel blocker vs diuretic. The anti-hypertensive and lipid-lowering treatment to prevent heart attack trial. *JAMA* 288: 2981-2997, **2002**.
58. Arnold JMO, *et al*: Prevention of heart failure in patients, in the HOPE study. *Circulation* 107: 1284-1290, **2003**.
59. Varon J: Treatment of acute severe hypertension: current and newer agents. *Drugs* 68(3), 283-297, **2008**.
60. Plosker GL: Tolvaptan. *Drugs* 70 (4), 443-454, **2010**.
61. Lyseng-Williamson, Katherine A, Keating GM: Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. *Drugs* 69 (6), 739-756, **2009**.
62. Walraven CV, Hart RG, *et al*: Oral anticoagulant vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. *JAMA* 288: 2441-2448, **2002**.

63. Mehta SR, Yusuf S, *et al*: The clopidogrel in unstable angina to prevent recurrent events (CURE) trial including a metaanalysis. *Eur Heart J* 21: 2033-2041, **2000**.
64. Grundy SM, *et al*: Implications of recent clinical trials for the National Cholesterol Education Programme, ATPIII guidelines. *Circulation* 110: 227-239, **2004**.
65. Heart Protection Study collaborative group: Effects of cholesterol lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. *Lancet* 363: 757-767, **2004**.
66. Niebyl JR: Clinical practice. Nausea and vomiting in pregnancy; *N Engl J Med* 363 (16): 1544-1550, **2010**.
67. Curran MP, Robinson DM: Aprepitant: a review of its use in the prevention of nausea and vomiting; *Drugs* 69(13): 1853-1878, **2009**.
68. Fischer Walker CL, Fontaine O, Young MW, Black RE: Zinc and low osmolarity oral rehydration salts for diarrhoea: A renewed call to action; *WHO Bull* 87: 780-786, **2009**.
69. Layer P, Andresen V: Review article: rifaximin, a minimally absorbed oral antibacterial for the treatment of traveller's diarrhoea; *Aliment Pharmacol Ther* 31(11): 1155-1164, **2010**.
70. Sazawal S *et al*: Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials; *Lancet Infect Dis*, 6: 374-382, **2006**.
71. Albanna AS, Menzies D: Drug resistant tuberculosis: what are the treatment options? *Drugs* 71(7): 815-825, **2011**.
72. India achieves National elimination of leprosy. *Ind J Leprosy* 78: 101, **2006**.
73. Jefferson T, Demicheli, V, *et al*: Antivirals for influenza in healthy adults: systematic review. *Lancet* 367: 303-313, **2006**.
74. Mohapatra PK, *et al*: Evaluation of chloroquine and sulphadoxine/pyrimethamine therapy in uncomplicated falciparum malaria in Indo-Myanmar border areas. *Trop Med and Internat Health* 10: 478-483, **2005**.
75. White NJ for SEAQUAMAT group: Artesunate versus quinine for treatment of severe falciparum malaria: a randomized trial. *Lancet* 366: 717-725, **2005**.
76. Rueangweerayut R, Phyto AP, *et al*: Pyronaridine-artesunate versus mefloquine plus artesunate for malaria. *N Engl J Med* 366: 1298-1309, **2012**.
77. Gargano N, *et al*: Therapeutic efficacy and safety of dihydroartemisinin-piperaquine versus artesunate-mefloquine in uncomplicated *Plasmodium falciparum* malaria in India, *Malaria Journal* 11-233, 1-12, **2012**.
78. Anvikar AR, *et al*: Artesunate-amodiaquine fixed dose combination for the treatment of *Plasmodium falciparum* malaria in India. *Malaria Journal* 11: 97, 1-8, **2012**.
79. Melaku Y, *et al*: Treatment of kala-azar in Southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy. *Am J Trop Med Hyg* 77: 89-94, **2007**.
80. Sundar S, *et al*: Injectable paromomycin for visceral leishmaniasis in India. *N Engl J Med* 356: 2571-2581, **2007**.
81. Patra P, *et al*: Efficacy of oral miltefosine in visceral leishmaniasis in rural West Bengal, India; *Ind J Pharmacol* 44: 500-503, **2012**.
82. Breastfeeding and maternal medication; *WHO/CDR* 95.11, **1995**.
83. *National Formulary of India*: 4th edn. Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare, Govt. of India, **2010**.

